Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences Corp Issues Q2 2013 Guidance Below Analysts' Estimates; Lowers FY 2013 Guidance


Tuesday, 23 Apr 2013 04:01pm EDT 

Edwards Lifesciences Corp announced that for second quarter of 2013, it expects total sales in the range of $500 million to $530 million and diluted earnings per share (EPS), excluding special items, between $0.75 and $0.79. For fiscal 2013, it expects sales in the range of $2.0 billion to $2.1 billion and earnings per diluted share, excluding special items, of $3.00 to $3.10. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $536 million and EPS of $0.81 for second quarter of 2013; revenue of $2.13 billion and EPS of $3.27 for fiscal 2013. 

Company Quote

98.41
-0.29 -0.29%
4:02pm EDT